Announcement PDF ASX ANNOUNCEMENT Actinogen Appendix 4E and 2025 digital annual report Sydney, 25 August 2025. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce its financial results for the year ended 30 June 2025. The Appendix 4E and 2025 digital annual report documents are attached. ENDS Dr. Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au Investors Media Michael Roberts Investor Relations M: +61 423 866 231 George Hazim Media & Public Affairs Australia M: +61 417 516 262 E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au Announcement authorised by the Board of Actinogen Medical About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health. Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making. Actinogen is currently developing its lead compound, Xanamem, as a promising new therapy for Alzheimer’s Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments. Clinical Trials The XanaMIA Phase 2b/3 Alzheimer’s disease trial is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 220 patients with mild to moderate AD and progressive disease, determined by clinical criteria and confirmed by an elevated level of the pTau181 protein biomarker in blood. Patients receive Xanamem 10 mg or placebo, once daily, and its ability to slow progression of Alzheimer’s disease is assessed with a variety of endpoints. The primary endpoint of the trial is the internationally-recognized CDR-SB (Clinical Dementia Rating scale – Sum of Boxes). The trial is being conducted in Australia and the US. Initial results from an interim analysis triggered by the 100th participant reaching 24 weeks of treatment are anticipated in January 2026 and final results Q4 2026. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 1 The XanaMIA-DUR Alzheimer’s disease open-label extension trial is an open-label trial of up to 24 months where all participants will receive active Xanamem 10 mg once daily. The trial will evaluate safety and a limited number of efficacy endpoints such as the CDR-SB. The trial will commence in Q1 2026 and be open to all former and current participants in the XanaMIA Phase 2b/3 trial. The XanaCIDD Phase 2a depression trial was a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 167 patients with moderate, treatment-resistant depression and a degree of baseline cognitive impairment. Participants were evenly randomized to receive Xanamem 10 mg once daily or placebo, in most cases in addition to their existing antidepressant therapy, and effects on cognition and depression were assessed. Trial results were reported in August 2024 and showed clinically and statistically significant benefits on depression symptoms with positive effects on the MADRS scale (a validated scale of depression symptom measurement) and the PGI-S (a valid patient reported assessment of depression severity). Cognition improved markedly and to a similar extent in both Xanamem and placebo groups. About Xanamem (emestedastat) Xanamem’s novel mechanism of action is to control the level of cortisol in the brain through the inhibition of the cortisol synthesis enzyme, 11β-HSD1, without affecting production of cortisol by the adrenal glands. Xanamem is a first-in-class, once-a-day pill designed to deliver high levels of cortisol control in the brain. To view Xanamem’s two-minute Mechanism of Action video, click here. Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent XanaCIDD trial demonstrated clinically and sometimes statistically significant benefits on depressive symptoms. The Company has studied 11β-HSD1 inhibition by Xanamem in approximately 400 volunteers and patients in eight clinical trials. Xanamem has a promising safety profile and has demonstrated clinical activity in patients with depression, patients with biomarker-positive Alzheimer’s disease and cognitively normal volunteers. High levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical. Disclaimer This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP. Actinogen Medical Limited ACN 086 778 476 Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 +61 2 8964 7401 | actinogen.com.au 2 ACTINOGEN MEDICAL LIMITED APPENDIX 4E 1. Company details Name of entity ACTINOGEN MEDICAL LIMITED ABN or equivalent company reference Financial year ended (‘reporting period’) Financial year ended (‘previous corresponding period’) 14 086 778 476 30 June 2025 30 June 2024 2. Results for announcement to the market Revenue from ordinary activities Loss from ordinary activities after tax attributable to members Net loss for the period attributable to members Net tangible asset per share (a) 30/06/2025 $ 685,253 30/06/2024 $ 291,021 Change % 135% Amount change $ 394,232 (14,732,263) (13,044,282) 13% (1,687,981) (14,732,263) (13,044,282) 13% (1,687,981) 0.005 0.007 (a) Includes right-of-use asset 3. Statement of comprehensive income Refer to attached financial statements. 4. Statement of financial position Refer to attached financial statements. 5. Statement of cash flows Refer to attached financial statements. 6. Statement of changes in equity Refer to attached financial statements. 7. Dividends/distributions No dividends declared in current or prior year. 8. Details of dividend reinvestment plan Not applicable. 9. Details of entities over which control has been gained or lost during the period Not applicable. 10. Details of associates and joint venture entities Not applicable. 11. Any other significant information needed by an investor to make an informed assessment of the Company’s financial performance and financial position Refer to attached financial statements. 12. Foreign entities Not applicable. ACTINOGEN MEDICAL LIMITED APPENDIX 4E 13. Commentary on results and explanatory information Actinogen Medical Limited (‘the Company’) incurred a net loss after tax for the financial year ended 30 June 2025 of $14,732,263 (2024: $13,044,282) Full year ended 30/06/2025 $ Full year ended 30/06/2024 $ 685,253 5,489,600 6,174,853 291,021 9,931,504 10,222,525 Research & development costs Employment costs Corporate & administration costs Finance costs Realised (loss) / unrealised gain on foreign currency Share-based payment expenses Amortisation expense Depreciation expense (right-of-use asset) Depreciation expense (office equipment) Total expenses (12,296,568) (4,434,666) (2,026,706) (48,890) (14,381) (1,663,705) (312,746) (80,964) (28,490) (20,907,116) (15,535,482) (4,195,292) (1,732,305) (24,292) (55,189) (1,307,416) (313,602) (82,179) (21,050) (23,266,807) Loss before income tax Income tax expense (14,732,263) - (13,044,282) - Loss for the year (14,732,263) (13,044,282) Interest revenue Other income Total revenue & other income Significantly more interest income was earned in the year as the company maintained a higher cash balance throughout the year, and carefully managed its cash on hand to maximise its earning potential. Research and development costs overall decreased due to the completion and close-out of the XanaCIDD study, and as the Phase 2b/3 XanaMIA study ramped up later in the financial year. There was a slight increase in employment costs as the company finalised recruitment of key team members during the year, and as a result of salary increases. Corporate and administration costs increased with greater investment in media and communications, business development and investor relations. For further information, refer to the Directors’ Report and the Financial Statements. 14. Audit This report is based on accounts which have been audited. Dr Steven Gourlay Managing Director Sydney, New South Wales 25 August 2025 Authorised for release by the Board of Directors. Annual Report 2025 Actinogen is advancing a revolutionary oral therapeutic, Xanamem®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation. ® Xanamem is a registered trademark of Actinoen Medical Limited Contents Who we are IFC Highlights 2 The Xanamem pipeline 3 MDD trial results 4 XanaMIA phase 2b/3 Alzheimer’s disease trial 6 The Alzheimer’s market 7 Chair’s letter 8 Chief Executive Officer’s letter 10 Vision and strategy 12 Operating & financial review 14 Board of directors 24 Executive leadership team 26 Directors’ report 28 Remuneration report (Audited) 31 Auditor’s independence declaration 44 Financial report 45 Directors’ declaration 70 Independent auditor’s report 71 Shareholder information 75 Corporate directory 78 Disclaimer This annual report may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered “at-risk statements” not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. Annual Financial Report 1 Highlights Planning for commercial readiness Pivotal XanaMIA phase 2b/3 AD clinical trial passes 100th participant milestone. Interim analysis scheduled for Jan 2026; final results Q4 2026 World Health Organization granted new and unique International Nonproprietary Name ‘emestedastat’ to Xanamem and also accepted in US as USAN2 Announced positive depression results from XanaCIDD phase 2a trial supporting Xanamem’s cortisol control mechanism & confirming clinical activity of 10mg daily dose Conducted successful Type C regulatory meeting on MDD1 with the US FDA to reach common understanding of path to marketing approval of Xanamem for MDD Published an academic manuscript in peerreviewed journal, Clinical Pharmacology in Drug Development detailing the multiple trials supporting the utility of Xanamem 10mg Completed production of 15kg scale-up batch of drug substance from contract manufacturer, Asymchem, to be manufactured in the US into Xanamem tablets Appointed experienced inaugural Chief Commercial Officer (CCO), Andy Udell, based in the USA to manage commercialization activities Completed an $11.1m capitalraising, received a $9.0 million R&D tax incentive rebate & established a $13.8m nondilutive R&D tax incentive funding facility. Funding secured to mid-late CY 20263 Attended & presented at significant international conferences and conducted meetings at industry gatherings to enable evaluation of potential value-add regional and global business development opportunities Delivered another in series of ’plain English’ Clinical Trials Science Forum (CTSF) neuroscience webinars titled: The critical importance of preparing for commercialization Initiated clinical pharmacokinetic trial and other ancillary studies. Commenced preparation for an ‘open-label’ extension trial beginning Q1 2026 to allow XanaMIA trial participants to continue with active Xanamem therapy Strengthened engagement and understanding among external stakeholders through a high-quality, two-minute mechanism-ofaction animation View here 1 MDD = major depressive disorder 2 USAN = A United States Adopted Name (USAN) is a unique nonproprietary name assigned to a medication marketed in the United States 3 Unless stated otherwise, all financial data is in Australian dollars 2 Actinogen Medical Limited The Xanamem pipeline Progressing Xanamem in Alzheimer’s disease, major depressive disorder and other neurological indications Indication Preclinical Phase 1 Alzheimer’s disease Phase 2b/3 interim analysis Jan 2026, final results late 2026 MDD Paused after phase 2a pending phase 2b/3 trial funding Fragile X syndrome Paused prior to phase 2 Phase 2 Phase 3 Open INDs Frontotemporal dementia Lewy-body dementia Potential next indications Parkinson’s disease Anxiety disorders MDD: Major depressive disorder Annual Financial Report 3 MDD trial results Further exploration of trial results showed encouraging activity for Xanamem when patients were also taking background Selective Serotonin Reuptake Inhibitor (SSRI) drugs – the commonest class of anti-depressant therapy in clinical use. MADRS depression scores favour Xanamem at Week 6 & 10 in patients also taking SSRI drugs (n = 76) • A clinically meaningful improvement in depression symptoms, measured by the MADRS score, was seen after 6 weeks of therapy vs. placebo, and was then greater and statistically significant after four weeks of “blinded” post-treatment follow up MADRS LS mean change from baseline (± SE) XanaCIDD depression trial shows positive Xanamem activity on top of background SSRI therapy • The placebo-subtracted treatment difference of 4.3 MADRS points is similar to that seen with currently approved anti-depressants • These data suggest that Xanamem could be beneficial as “add-on” therapy to SSRI drugs Xanamem (n=37) Baseline Placebto (n=39) Week 2 Week 4 Week 6 Week 10 PT 0 • Developing Xanamem in combination with SSRI drugs is a viable and pragmatic pathway to approval in major depressive disorder PT 4.2-point difference Cohen’s d = 0.64 p = 0.03 -2 BETTER -4 -6 -8 EOT 2.6-point difference Cohen’s d = 0.38 p = 0.15 -10 -12 FOLLOW UP ON TREATMENT Patient Global Impression – Severity scores favour Xanamem from Week 2 in patients also taking SSRI drugs (n = 75) Xanamem (n=36) Baseline Week 2 Placebo (n=39) Week 4 Week 6 Week 10 PT PGI-S LS mean change from baseline (± SE) 0 -0.2 PT 0.59-point difference Cohen’s d = 0.62 -0.4 -0.6 -0.8 -1 -1.2 -1.4 EOT 0.41-point difference Cohen’s d = 0.43 -1.6 ON TREATMENT FOLLOW UP Abbreviations: MADRS = Montgomery-Åsberg Depression Rating Scale; EOT: End of Treatment; PT: Post Treatment; SSRI = selective serotonin reuptake inhibitor; 4 Actinogen Medical Limited BETTER The XanaCIDD depression benefits show that controlling cortisol levels in key areas of the brain has a clinically important effect, increasing our confidence in positive outcomes for trials in depression, Alzheimer’s disease and other diseases where cortisol plays a role. Analysis of patients also taking SSRI drugs suggests that Xanamem’s benefit on depressive symptoms may be greater in this patient population and points us toward studying this combination in future clinical trials. Dr Dana C Hilt Actinogen’s Chief Medical Officer Annual Financial Report 5 XanaMIA phase 2b/3 Alzheimer’s disease trial rapidly approaching major milestones 10mg Xanamem vs Placebo (n=220) Interim Analysis Final Results January 2026 Late 2026 2026 2027 and beyond More than 50% enrolled Target full enrolment Q3 2025 Q4 2025 Open label extension commences Q1 2026 Key trial criteria Key Inclusion Criteria Primary Endpoint Key Secondary Endpoints Implementation • Blood pTau biomarker positive • CDR-SB (functional and cognitive measure) @36 weeks • Cognitive Test Battery (7 cognitive measures well‑validated in the Alzheimer’s field) • Enrolment at 15 Australian & 20 US sites • Mild-moderate Alzheimer’s by NIA‑AA criteria • Also measured at 12 and 24 weeks • Amsterdam Activity of Daily Living (functional measure) NIA-AA=National Institute of Aging - Alzheimer’s Association; CDR-SB Clinical Dementia Rating Scale – Sum of Boxes 6 Actinogen Medical Limited • Interim analysis January 2026 (efficacy futility & safety) • High quality endpoint monitoring The Alzheimer’s market Large and unsatisfied Alzheimer’s market Growing Alzheimer’s disease market - U.S. 13.8M $1T 91% of neurologists agree there is a high unmet need for DMTs for early AD 86% of neurologists expect their approach to treating early AD will change over the next 5 years as novel DMTs launch 7.2M $384B 2025 2060 2025 (Est.) Number of patients (65+ years old) 2050 (Est.) Cost to treat (USD) Sources: U.S. burden of Alzheimer’s disease, related dementias to double by 2060 | CDC Online Newsroom | CDC, US Alzheimer’s Prevalence Surpasses 7 Million Source: The Cost of Dementia in 2025 - April 23, 2025 - USC Schaeffer Positive reaction to Xanamem’s potential advantages per clinician feedback Advantages of Xanamem (Unaided) % of respondents 64% “Oral agent with distinctive mechanism of action, no safety concern.” 38% 32% 31% “More efficacious, oral, no concern for ARIA, can be used in more advanced AD.” 18% 12% Oral Safety profile Novel Efficacy MOA No ARIA No DDI 8% 13% Tolerability Other profile “It appears to be quite safe. There is little work to be done on the part of the clinician or the patient (dosing, labs, titration, etc.)” Above and right: Spherix Global Insights: Market Dynamix Early Alzheimer’s Disease (US) Q2 2025 (n=101) and Custom Quantitative Analysis (US) July/August 2025 (n=91) DMTs: Disease modifying therapies ARIA: Amyloid-related imaging abnormalities Annual Financial Report 7 Chair’s letter Actinogen has continued to make excellent progress in the fulfillment of its business priorities and strategic objectives in the 2025 financial year. Dear Shareholder, I am pleased to present to you the Actinogen Medical Annual Report for the financial year ended 30 June 2025 reflecting on a period of significant progress in a dynamic global environment. The past year has been marked by a rebound of interest in small-cap biotechnology, particularly those advancing into later stages of clinical development. In both the United States and Australia, investor sentiment has gradually improved, buoyed by more favourable economic conditions and renewed appetite for innovation in healthcare. This has led to a general rotation of capital into high-quality small- and mid-cap biotechs, especially those with promising phase 2/3 assets. Actinogen is in exactly that “sweet spot” with its Xanamem pivotal trial program. Against this backdrop, Actinogen has delivered a year of meaningful progress. Our novel, small molecule asset, Xanamem, advanced in two major indications—Alzheimer’s disease and major depressive disorder—both of which represent areas of significant unmet medical need. For now, Alzheimer’s disease is the primary focus for company resources given the immense potential value a new, oral therapy for this disease represents. Addressing a significant global health need Alzheimer’s disease remains one of the most pressing healthcare challenges of our time. With over 55 million people affected globally and no cure currently available, the demand for effective therapies is only growing. Recent drug approvals for anti-amyloid infusion therapies, that have only modest benefit, underscore the opportunity for next-generation therapies such as oral Xanamem. Actinogen’s focus on modifying the progression of Alzheimer’s by controlling brain cortisol positions us as unique in this space. There is no other similar drug in development for CNS diseases to our knowledge. We are proud to be contributing to a global effort to slow, halt, or even reverse the functional and cognitive decline associated with this devastating condition. Executive leadership I would also like to commend the outstanding performance of our high-calibre senior leadership team, impeccably led by Dr. Steven Gourlay. Their strategic leadership, scientific knowledge and expertise, and unwavering commitment have been instrumental in driving the company’s progress. We also welcomed Mr Andrew (Andy) Udell to the team as Chief Commercial Officer. His commercial expertise adds valuable depth to our executive team as we complete later-stage clinical development and prepare the path to product launch. I also extend my appreciation to our wider executive team, dedicated employees, and key contractors. Their professionalism and dedication have been vital in maintaining a highly effective and efficient clinical development program and the corporate operations required of a publicly listed biotechnology company. Their collective efforts continue to drive Actinogen forward with purpose and momentum. 8 Actinogen Medical Limited Board, corporate governance and advisory boards Annual General Meeting Our Board remains committed to the highest standards of corporate governance and management oversight capability. This year’s Annual General Meeting will be held in person in Sydney on Wednesday 19 November 2025, and we look forward to engaging with shareholders on our progress and future plans. Details of the meeting time and Sydney location will be announced in due course. During the year, we reviewed our governance practices and reassessed the Board skills matrix to identify areas for enhancement and future capability needs. We continue to evolve our governance framework to reflect the company’s growth and operational complexity. Our commitment to transparency and accountability remains strong, with all key corporate policies and governance materials available on our website. This framework supports the effective management and execution of both our longterm strategic vision and annual priorities. I would like to express my sincere appreciation to my fellow Board members for their valuable contributions and leadership throughout the year. Their strategic insight, governance leadership, and steadfast commitment have been instrumental in supporting Actinogen as we continue to navigate the complexities of late-stage clinical development. The Board also acknowledges the valuable insights and guidance provided by our scientific and medical advisory boards, which provide strategic guidance as we navigate clinical and regulatory pathways. Further details on the Actinogen corporate board, advisory boards and senior executive personnel can be found on the company’s website. Capital management We strengthened our financial position through a successful capital raise of $11.1 million, the completion of which was announced in October 2024, comprising an $8.1 million placement and a $3.0 million Share Purchase Plan. Subscribers also received listed options as part of the capital raising, so the company now has two series of options trading on the ASX. This provides flexibility for shareholders and potential capital for future growth if and when those options are exercised. In addition, we received a $9.0 million R&D tax incentive rebate in October 2024 for the 2024 financial year and recently secured access to up to A$13.8 million via a non‑dilutive loan funding facility secured against the company’s future Research and Development Tax Incentive (RDTI) rebates. Outlook We enter the new financial year with optimism. The interim analysis of efficacy and safety of our pivotal XanaMIA AD trial, expected in January 2026, will be an important milestone. Assuming it is positive, it will provide valuable momentum for the clinical program and support ongoing engagement with potential partners and stakeholders. It will also mean that we will be even closer to final topline trial results expected late in 2026, which are keenly anticipated. In closing, I would like to sincerely thank you, our shareholders, for your continued support and confidence in Actinogen. Your backing enables us to pursue our work with focus and determination, and we are grateful for your ongoing engagement as we progress through this pivotal phase of development. We look forward to sharing further updates with you over the coming year as we continue working to deliver meaningful innovation for patients and value for shareholders. Dr Geoff Brooke Chair 25 August 2025 If you have any questions relating to your shareholding in Actinogen, please contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia). Visit the Automic website https://investor. automic.com.au/#/home to register as an ACW shareholder or log in to your existing account. Annual Financial Report 9 Chief Executive Officer’s letter I am pleased to provide you with an update on Actinogen Medical’s progress over the past year. Since July 2024, we have made significant strides in advancing our clinical programs, strengthening our financial position, and preparing for commercialization of our lead asset, Xanamem. Clinical Development Milestones and Peer-Review Publications Dear Shareholder, Approaching key Xanamem pivotal trial results in Alzheimer’s disease. Our commitment to developing Xanamem as a novel therapy for Alzheimer’s disease (AD) continues to yield promising results. In June 2025, we reached a major milestone with the enrolment of the 100th participant in our XanaMIA phase 2b/3 AD trial. This achievement sets the stage for our interim analysis in January next year, which is expected to provide valuable insights into the efficacy and safety of Xanamem in this population. The interim analysis will be conducted by an Independent Data Monitoring Committee and look at available data for participants at 12, 24 and 36 weeks of treatment. Full enrolment of all 220 participants in the XanaMIA trial is expected by the time of the interim analysis, with topline, final results for 36 weeks of treatment expected in Q4 2026. A new “open label” extension trial to provide active Xanamem to all participants who complete the XanaMIA trial will start enrolment in Q1 of 2026. Earlier in the year, our Chief Medical Officer presented positive depression data from the XanaCIDD phase 2a trial at the American Psychiatric Association 2025 conference, reinforcing the therapeutic potential of Xanamem in major depressive disorder (MDD), AD and other brain diseases. The finding of clinical benefits on depressive symptoms confirms the clinical activity in the brain of the 10 mg dose of Xanamem – highly relevant to the XanaMIA trial where the same dose is used. The XanaCIDD data were discussed in our Type C meeting with the FDA in March 2025, where we clarified the regulatory pathway for Xaname